[go: up one dir, main page]

EP1297108A2 - Lignees cellulaires et dosages a base de cellules permettant d'identifier des modulateurs de recepteurs d'androgenes - Google Patents

Lignees cellulaires et dosages a base de cellules permettant d'identifier des modulateurs de recepteurs d'androgenes

Info

Publication number
EP1297108A2
EP1297108A2 EP01944616A EP01944616A EP1297108A2 EP 1297108 A2 EP1297108 A2 EP 1297108A2 EP 01944616 A EP01944616 A EP 01944616A EP 01944616 A EP01944616 A EP 01944616A EP 1297108 A2 EP1297108 A2 EP 1297108A2
Authority
EP
European Patent Office
Prior art keywords
cell line
compound
androgen receptor
artificial sequence
stable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01944616A
Other languages
German (de)
English (en)
Inventor
Jacek Ostrowski
Joyce Driscoll
John Lupisella
Mark Salvati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of EP1297108A2 publication Critical patent/EP1297108A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Definitions

  • the invention relates to cell lines and methods for using these cell lines in the identification of compounds having biological activity.
  • the invention relates to muscle cell lines stably transfected with an androgen receptor and reporter gene useful in the identification of compounds which are modulators of the androgen receptor.
  • the androgen receptor is a member of the steroid nuclear-receptor superfamily of ligand-dependent transcription factors and is widely distributed among reproductive and nonreproductive tissues, including the prostate and seminal vesicles, male and female genitalia, skin, testis, ovary, cartilage, sebaceous glands, hair follicles, sweat glands, cardiac muscle, skeletal and smooth muscle, gastrointestinal vesicular cells, thyroid follicular cells, adrenal cortex, liver, pineal, and numerous brain cortical and subcortical regions, including spinal motor neurons (Negro-Vilar, A. JCE&M 1999 54(10) : 3459-62) .
  • DBD DNA binding domain
  • LBD 261 residue ligand-binding domain
  • AR is an important target in multiple areas of drug discovery and patient therapy.
  • inhibitors (antagonists or partial antagonists) of the androgen receptor function are useful for the treatment of androgen dependent prostate cancer while agonists or partial agonists of the AR are applicable to the treatment of breast cancer.
  • agonists or partial agonists of the androgen receptor function are useful for the treatment of age-related diseases and conditions of cachexia in several disease states including, but not limited to, AIDS.
  • Functional AR has also been identified in various bone cells and androgen administration has beneficial effects on skeletal development and maintenance in men and women.
  • U.S. Patent 5,071,773 describes an assay for identifying hormone intracellular receptors, ligands for these receptors and proteins capable of transcriptionally activating the hormone intracellular receptors.
  • the assays involve use of a cell containing DNA encoding a hormone response element such as a promoter linked to an operative reporter gene and DNA encoding the intracellular receptor protein.
  • a hormone response element such as a promoter linked to an operative reporter gene
  • a hormone intracellular receptor complex forms and is delivered to an appropriate DNA binding region, thereby activating the hormone response element, which in turn leads to expression of the product encoded by the reporter gene.
  • Activation of the reporter gene is detected in accordance with known procedures for detection of the reporter gene.
  • U.S. Patent 6,017,924 discloses non-steroidal compounds characterized as high affinity, high specificity agonists, partial agonists (i.e. partial activators and/or tissue-specific activators) and antagonists for androgen receptors based upon a "cis-trans" or "co-transfection” assay.
  • Non-steroidal compounds characterized as high affinity, high specificity agonists, partial agonists (i.e. partial activators and/or tissue-specific activators) and antagonists for androgen receptors via the "cis-trans” or "co-transfection” assay are also described in WO 01/16108, WO 01/16133, and WO 01/16139. This co-transfection assay (Evans et al .
  • CV-1 cells African green monkey kidney fibroblasts
  • plasmid pRShAR containing the human AR under the constitutive control of the SV40 promoter
  • MTV-LUC reporter plasmid MTV-LUC containing the cDNA of firefly luciferase under the control of a mouse mammary tumor virus (MTV) long terminal repeat.
  • MTV mouse mammary tumor virus
  • coli ⁇ -galactosidase is included as an internal control for evaluation of transfection efficiency and compound toxicity.
  • Hydroxyflutamide a known AR antagonist in most tissues, has also been suggested to function as a selective AR modulator (SARM) for effects on IL-6 production by osteoblasts (Hofbauer et al . J. Bone Miner. Res. 1999 14:1330-1337). Selectivity of hydroxyflutamide was assessed by evaluating the proliferation and differentiation of a human fetal osteoblast cell line (HFOB/AR-6) that expresses a mature osteoblast phenotype and a physiological number of androgen receptors in the presence of this compound.
  • HFOB/AR-6 human fetal osteoblast cell line
  • Hydroxyflutamide and Casodex both known to be full AR antagonists in most tissues, have also been shown, in AR-transfected PC3 cells, to activate MAP kinases Erk-1 and Erk-2 in an AR dependent fashion similar to dihydrotestosterone (DHT; Peterziel et. al . Oncogene 18, 6322-6329 (1999) ) .
  • the compound LGD2226 a non-steroidal AR agonist, has also been characterized as a selective androgen receptor modulator for use in the treatment of androgen- related diseases such as osteoporosis, male hormone replacement, male and female sexual dysfunction and cachexia based upon its activity in the CV-1 assay described supra (SCRIP - World Pharmaceutical New FILED 12 May 2000; WO 01/16108; WO 01/16133; and WO 01/16139).
  • U.S. Patent 5,952,488 describes a bioassay for androgenic materials in cell culture wherein HeLa cells or PC-3 cells are transiently transfected or stably integrated with a DNA sequence cloned from the probasin (PB) gene promoter region coupled to a CAT reporter gene .
  • PB probasin
  • U.S. Patent 5,506,102 describes methods and assays useful in screening compounds for potential antagonists of steroid intracellular receptor mediated transcription wherein cells are transfected with a first vector encoding the intracellular receptor, a second vector encoding the PR-A isoform of human progesterone receptor and a third vector encoding a reporter gene .
  • An object of the present invention is to provide muscle cell lines comprising a mammalian androgen receptor stably introduced into said muscle cells. These cell lines are useful in functional transactivation assays to assess the efficacy of compounds as androgen receptor modulators in a muscle cell background.
  • Another object of the present invention is to provide functional transactivation assays for use in assessing the efficacy of compounds as androgen receptor modulators in a muscle cell background via these stable C2C12 mouse skeletal muscle cell lines comprising the mammalian androgen receptor.
  • Yet another object of the present invention is to provide androgen receptor modulators, and in particular selective androgen receptor modulators, identified via functional transactivation assays with stable C2C12 mouse skeletal muscle cell lines comprising a mammalian androgen receptor.
  • the present invention relates to muscle cell lines stably introduced with a mammalian androgen receptor and reporter gene .
  • the muscle cell line comprises stable C2C12 mouse skeletal muscle cells.
  • other exemplary muscle cells useful in the present invention include, but are not limited to, mouse G-7, G-8, P19 and Sol8 cells, rat H9c2(2-1), L6 and L8 cells, and human SJRH30 (RMS13) cells.
  • the muscle cell lines of the present invention further comprise a mammalian androgen receptor which is stably introduced into the muscle cells.
  • Androgen receptors useful in the present invention have been isolated from various mammalian species. These receptors and their sequences have been described in detail in the prior art. For example, see U.S. Patent 5,614,620.
  • rat androgen receptors are set forth in Genbank Accession No. M23264 and J05454, as well as by Chang et al . (Science 1988 240 (4850) : 324-326) .
  • Mouse androgen receptors are set forth in Genbank Accession No. M37890 and by Gaspar et al. (Proc. Natl Acad. Sci.
  • the cell lines of the present invention comprise a rat androgen receptor.
  • the cell lines of the present invention are useful in assessing the activity of compounds as androgen receptor modulators in a muscle cell background.
  • the cell line comprises stable C2C12 mouse skeletal cells containing a full length rat androgen receptor such as that set forth in GenBank Accession No. M23264. This cell line is referred to herein as Stable 1.
  • Stable 1 To generate the Stable 1 cell line containing the full length rat androgen receptor (rAR) , the C2C12 mouse skeletal cell line (Yaffe D. and Saxel, O.
  • pIRESneo/rAR were transfected into C2C12 cells using LipofectAmine PlusTM reagent (Gibco BRL) with 250 ⁇ l plus reagent and 375 ⁇ l lipofectamine reagent in 10 milliliters optiMEM media (Gibco BRL) in accordance with the manufacturer's instructions.
  • Stable 1 growth media Dulbecco's modified Eagle medium (DMEM) high glucose supplemented with 10% FBS, IX sodium pyruvate and 0.5X antibiotic-antimycotic (all from Gibco BRL)
  • Stable 1 growth media a growth media plated onto each of five 10-cm culture plates. The following day, the media was removed from each dish and replaced with 4.5 milliliters optiMEM. Two milliliters of the transfection mixture were then added to each dish. After a three hour incubation, the transfection media was removed and replaced with 6.5 milliliters of growth media. The cells were allowed to grow for 24 hours in non-selection media.
  • the cells were split 1:15 into Stable 1 growth media supplemented with 800 ⁇ g/ml G418 and allowed to propagate as separate clonal cell lines . After fourteen days, a total of 80 resistant clones were isolated. Clones exhibiting normal growth characteristics were transiently transfected with the enhancer/promoter/reporter construct, pGL3/2X DR-l/luciferase.
  • Stable 1 cells are identified as clones showing a significant increase in luciferase activity, as measured via the Steady-GloTM Luciferase Assay System (Promega) , upon addition of 0.1 ⁇ M dihydrotestosterone (DHT) .
  • DHT dihydrotestosterone
  • the Stable 1 cell line exhibits approximately a 12-fold increase or greater in luciferase activity upon addition of the DHT.
  • Stable 1 cells of the present invention comprising a stable C2C12 mouse skeletal cell line containing a full length rat androgen receptor were sent for deposit on June 12, 2001 to the American Type Culture Collection (ATCC) , 10801 University Boulevard, Manassas, VA USA 20110-2209. Twenty-five vials of Stable 1 cells, with an approximate activity of 30,000 specific relative luminescence units
  • the stable C2C12 mouse skeletal cell line contains a full length rat androgen receptor plus an enhancer/promoter/reporter construct .
  • This cell line is referred to herein as Stable 2.
  • the enhancer comprises an androgen response element (ARE) .
  • ARE androgen response element
  • Exemplary AREs used in these constructs include, but are not limited to, C3-1, PB-ARE, and DR1.
  • C3-1 is a consensus ARE/GRE (glucocorticoid receptor response element) isolated from the C3 subunit promoter of the gene for rat prostatic binding protein.
  • 2XC3, containing two C3-1 elements, comprises a consensus enhancer sequence for AR and GR (Claessens et al . J. Biol. Chem. 1996 271:19013-19016).
  • PB-ARE is an androgen receptor specific response element isolated from the promoter of the rat probasin gene (Claessens et al . J. Biol. Chem. 1996 271:19013-19016).
  • the DR1 response element is also androgen receptor specific, however, it was derived synthetically from a pool of degenerate oligonucleotides containing a consensus ARE/GRE using a random sequence selection and amplification method.
  • IX DR- 1, containing 1 DR-1 element, and 2X DR-1, containing two DR-1 elements, have both been reported as specific for AR (Zhou et al. J. Biol. Chem. 1997 272:8227-8235) .
  • Each DR1 element consists of two AR core binding sites oriented as an overlapping direct repeat (Zhou et al .. J. Biol. Chem. 1997 272:8227-8235) .
  • promoters can also be used in these constructs.
  • Exemplary promoters include, but are not limited to, SV40, CMV, beta-globin, and HSVtk. However, as will be understood by those of skill in the art upon reading this disclosure, other promoters useful in the present invention can be routinely selected.
  • the enhancer/promoter construct of the Stable 2 cell line comprises pGL3/2X DR-1 which carries the stronger SV40 promoter.
  • 2XDR-1 was reported to be an AR specific response element in CV-1 cells (Zhou et. al . J. Biol. Chem. 1997 272:8227-8235). It was developed by random mutagenesis of an AR/GR consensus enhancer sequence. Experiments described in detail in Example 2 showed 2X DR-1 to exhibit better stimulation and selectivity upon addition of DHT as compared to enhancer/promoter constructs comprising AREs C3 , IX DR-1, as well as PB-ARE.
  • Examples include, but are not limited to, luciferase, beta-galactosidase, secretory alkaline phosphatase, beta-lactamase, numerous green fluorescence proteins, and chloramphenicol acetyltransferase .
  • the reporter gene is luciferase.
  • pGL3/2X DR- 1/luciferase cells of the Stable 1 cell line were cotransfected with a plasmid containing the enhancer/promoter/reporter construct and a plasmid conferring resistance to hygromycin B (pcDNA3. l-/Hygro, Invitrogen, Carlsbad, CA) . Specifically, 60 ⁇ g pGL3/2XDR-l luciferase and 15 ⁇ g pCDNA3.
  • l-/Hygro were transfected into Stable 1 cells using LipofectAMINE PlusTM reagent (Gibco BRL) with 300 ⁇ l plus reagent and 450 ⁇ l lipofectamine reagent in 12 milliliters optiMEM media (GibcoBRL) in accordance with the manufacturer's instructions.
  • Cells (6.0 x 10 5 ) in 10 milliliters of Stable 1 growth media supplemented with 800 ⁇ g/ml G418 were plated onto each of six 10-cm culture plates. The following day, the media was removed from each dish and replaced with 4.5 milliliters optiMEM. Two milliliters of the transfection mixture were then added to each dish.
  • the transfection media was removed and replaced with 6.5 milliliters of Stable 1 growth media.
  • the cells were allowed to grow overnight and then split 1:18 and 1:24 into Stable 1 growth media supplemented with 800 ⁇ g hygromycin B to select for individual cells stably transfected with the enhancer/promoter/reporter construct as well as hygromycin B resistance and then allowed to propagate as separate clonal lines.
  • resistant clones were isolated and clones exhibiting normal growth characteristics were tested for luciferase activity in the presence of 0.1 ⁇ M DHT. Clones with activities ranging from 3- to 12-fold increase over background were expanded.
  • the Stable 2 cell line exhibits a 12X increase or greater over background in luciferase activity upon addition of the DHT with an EC 50 in the sub-nanomolar range. The expected activity was exhibited when the Stable 2 cells were exposed to the other reference compounds.
  • Stable 2 cells of the present invention comprising a stable C2C12 mouse skeletal cell line containing a full length rat androgen receptor and a stably transfected pGL3/2X DR-l/luciferase reporter were sent for deposit on June 12, 2001 to the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, VA USA 20110- 2209. Twenty-five vials of Stable 2 cells, with an approximate activity of 30,000 specific relative luminescence units (RLUs) in the presence of 100 nM DHT in the transactivation assay described infra, were shipped to the ATCC.
  • the ATCC Deposit Number for the Stable 2 cell line is XXX.
  • the present invention also relates to functional transactivation assays developed to assess the activity of compounds as androgen receptor modulators in a muscle cell background via detection of expression of a reporter gene.
  • modulator for purposes of the present invention, it is meant to be inclusive of agonists, partial agonists, antagonists, and/or partial antagonists of AR.
  • efficacy of a compound as an androgen receptor agonist or partial agonist is assessed by contacting either Stable 1 cells transiently transfected with an androgen response element, a promoter and a reporter gene or Stable 2 cells with a compound and detecting reporter gene expression in the cells in the presence of the compound.
  • An increase in reporter gene expression in the cells in the presence of the compound, as compared to control cells not contacted with or exposed to the compound, is indicative of the compound being an androgen receptor agonist or partial agonist in muscle cells.
  • Efficacy of a compound as an androgen receptor antagonist or partial antagonist is assessed by a competition assay wherein the ability of a compound to prevent the induction of expression of a reporter gene by DHT in Stable 1 or Stable 2 cells is determined.
  • approximately 1 nM DHT is used in the assay to induce expression of the reporter gene.
  • a decrease in reporter gene expression in the presence of the compound as compared to control cells exposed to DHT, but not contacted with the compound is indicative of the compound being an androgen receptor antagonist or partial antagonist in muscle cells.
  • These assays can be used to determine the concentration at which the compound inhibits DHT induction by 50%, also referred to as the IC 50 .
  • ARTA Stable 1 a first assay of the present invention, referred to herein as Androgen Receptor Transactivation Assay (ARTA) Stable 1, uses the Stable 1 cell line, which stably expresses the full length rat androgen receptor but requires the transient transfection of an enhancer/promoter/reporter construct.
  • ARTA Androgen Receptor Transactivation Assay
  • Stable 1 cells are plated, preferably in a 96 well format, at approximately 5,000 to 10,000 cells/well, preferably 6,000 cells/well, in high glucose DMEM without phenol red (Gibco BRL, Cat. No.: 21063-029) containing 10% charcoal and dextran treated FBS (HyClone Cat. No.: SH30068.02), 50 mM HEPES Buffer (Gibco BRL, Cat. No.: 15630-080), IX MEM Na Pyruvate (Gibco BRL, Cat. No.: 11360-070), 0.5X Antibiotic- Antimycotic, and 800 ⁇ g/ml Geneticin (Gibco BRL, Cat. No.: 10131-035) .
  • the cells are transfected with an enhancer/promoter/reporter construct such as pGL3/2XDR-l/luciferase.
  • the transfection is performed using LipofectAMINE PlusTM Reagent (Gibco BRL, Cat. No.: 10964- 013) .
  • pGL3/2XDR-l/luciferase DNA (approximately 5 ng/well) and a carrier, such as Salmon Sperm DNA (50 ng/well) or a generic plasmid DNA, are diluted with 5 ⁇ l/well Opti-MEM media (Gibco BRL, Cat. No.: 31985-070).
  • Opti-MEM media Gibco BRL, Cat. No.: 31985-070
  • 0.5 ⁇ l/well Plus reagent is added. This mixture is incubated for 15 minutes at room temperature.
  • LipofectAMINE reagent is diluted with 5 ⁇ l/well Opti-MEM.
  • the DNA mixture is then combined with the LipofectAMINE mixture and incubated for an additional 15 minutes at room temperature. During this time, the media from the cells is removed and replaced with 60 ⁇ l/well of Opti-MEM. To this is added 10 ⁇ l/well of the DNA/LipofectAMINE transfection mixture. The cells are incubated for 4 hours. The transfection mixture is removed from the cells and replaced with 90 ⁇ l of the high glucose DMEM described supra .
  • transfection methods which can be used in the present invention include, but are not limited to, DEAE- dextran, calcium phosphate, direct microinjection, electroporation, and biolistic particle delivery.
  • Compounds to be tested for activity in this assay are then placed in each well.
  • 10 ⁇ l of appropriate compound dilution is placed in each well. It is preferred that a range of concentrations of compound, i.e. from about 0.001 nM to 3000 nM, be tested. It is also preferred that initial dilutions of compounds be made in dimethylsulfoxide or ethanol and that subsequent dilutions be made in assay media. Twenty-four hours later activity of the compound is detected via a detection system such as the Steady-GloTM Luciferase Assay System (Promega, Cat. No.: E2520) , or via other luciferin substrates (Tropix or Packard Biosciences) according to the manufacturers' instructions .
  • a detection system such as the Steady-GloTM Luciferase Assay System (Promega, Cat. No.: E2520) , or via other luciferin substrates (Tropix or Packard Bioscience
  • a second assay of the present invention uses the Stable 2 cell line, derived from Stable 1 which stably expresses both rat androgen receptor and an ARE enhancer/promoter/reporter construct .
  • the enhancer/promoter/reporter construct used in this system preferably comprises pGL3/2XDR-l/luciferase.
  • Stable 2 cells are plated, preferably in 96 well format, at approximately 5,000 to 10,000 cells/well, preferably 6,000 cells/well, in high glucose DMEM without phenol red (Gibco BRL, Cat.
  • Compounds to be tested for activity in this assay are then placed in each well.
  • a 10 ⁇ l aliquot of compound at a concentration ranging from about 0.001 nM to 3000 nM is placed in each well. It is preferred that initial dilutions of a compound be made in dimethyl sulfoxide or ethanol and subsequent dilutions be made in assay media. After 24 hours, activity is detected via the Steady-GloTM Luciferase Assay System (Promega, Cat. No. : E2520) or via other luciferin substrates (Tropix or Packard Biosciences) according to the manufacturers' instructions .
  • An agonist or partial agonist for purposes of the present invention, is defined as any compound that achieves 50% of the maximal activity of DHT at a concentration less than or equal to 3000 nM (3 ⁇ M) in the transactivation assay of the present invention.
  • An antagonist or partial antagonist for purposes of the present invention, is defined as any compound that is able to inhibit by 50% the maximal activity of 1 nM DHT at a concentration less than or equal to 3000 nM in the transactivation assay of the present invention.
  • the assays of the present invention are particularly useful in identifying specific or selective androgen receptor modulators or SARMs .
  • SARM it is meant an androgen receptor modulator exhibiting a difference-in-kind of the modulation effected in one type of tissue, i.e. tumors, containing the androgen receptor relative to the modulation effected in other tissues, i.e. nontumor tissues, containing the androgen receptor.
  • the agonist or antagonist activity of a potential SARM is measured in an assay of the present invention to ascertain activity of the compound in a muscle cell background.
  • Activity of the potential SARM can also be measured in other nontumor cells lines such as primary rat prostate epithelial and stromal cells, primary guinea pig smooth muscle cells, primary smooth-muscle cells from immature (I-PSMC) or adult (A-PSMC) rat penis, primary rabbit smooth muscle cell line, prostatic smooth muscle cell line PS-1, prostatic smooth muscle cell line PSMC1, mouse bone cell cultures and osteoblasts cells and primary rat seminal vesicle lines SVC-1 and SCV-2.
  • hormone-dependent tumor cell lines which can be used for screening potential SARMs include, but are not limited to, human breast tumor cell line MDA MB453, human breast tumor cell line ZR-75-1, murine breast line Shionogi, rat prostate adenocarcinoma line Dunning R-3327, human prostate tumor cell line MDA PCa 2a and PCa 2b, human prostate cell line LNCap, human prostate tumor cell line CWR22, human prostate tumor cell line LuCaP 35 and LuCaP 23.12, human prostate cell line LAPC-4 and LAPC-9, human prostate tumor cell line PC-295, human prostate tumor cell line PC-310, and human osteosarcoma cell line MG-63.
  • SARMs identified via assays of the present invention are those exhibiting antagonist activity in tumors versus agonist activity in other, nonmalignant tissues containing the androgen receptor.
  • SARMs identified in accordance with these assays as agonists of androgen receptors in muscle tissue are useful in inhibiting muscle wasting and cachexia oftentimes observed in patients suffering from cancer or AIDS.
  • the following nonlimiting examples are provided to further illustrate the present invention.
  • Androgen Receptor Plasmid pIRESneo/rAR The rat androgen receptor (GenBank Accession No.
  • luciferase reporter constructs containing known androgen receptor response elements were prepared in the pGL3-Promoter vector (Promega Corporation, Madison, WI) .
  • pGL3/lXDR-l/Lucif erase was prepared in the pGL3/lXDR-l/Lucif erase
  • oligonucleotide DR-l(F) has the sequence :
  • the oligonucleotide DR-l(R) has the sequence: 5' -TCGATCAGTCTGTTCCGTTCCTTCAGGAC-3' (SEQ ID NO: 2).
  • a second DR-1 response element was inserted upstream of the existing DR-1 element in pGL3/lXDR-l/Luciferase by annealing equimolar amounts of the complementary oligonucleotide ⁇ XDR-I(F) and 1XDR-1 (R) and then ligating into Sacl/Xhol digested pGL3/lXDR-l/Luciferase plasmid.
  • the oligonucleotide 1XDR-1 (F) has the sequence: 5' -CGTCCTGAAGGAACGGAACAGACTGA-3' (SEQ ID NO: 3).
  • the oligonucleotide ⁇ XDR-I(R) has the sequence: 5' -TCGATCAGTCTGTTCCGTTTTTCCTTCAGGACGAGCT-3 ' (SEQ ID NO: 4).
  • oligonucleotide C3-1(F) has the sequence :
  • the oligonucleotide C3-1(R) has the sequence: 5' -TCGATTGAGAACATCACGTACTATGTAC-3' (SEQ ID NO: 6).
  • oligonucleotide sequence of PB-ARE-2F has the sequence:
  • the oligonucleotide sequence of PB-ARE-2R has the sequence: 5' -TCGACCGTAAAGTAACTCCAAGAACCTATTAC-3 ' (SEQ ID NO: 8).
  • pGL3 /HSVtk This vector was prepared by replacing the SV40 promoter in pGL3-Promoter plasmid (Promega Corporation) with the HSVtk (Herpes Simplex Virus Thymidine Kinase) promoter from pRL-TK (Promega Corporation) . Both promoters are contained within Bgl II/Hind III fragments and were easily exchanged by ligating the HSVtk fragment from pRL-TK into the Bgl II/Hind II digested pGL3 -Promoter vector.
  • HSVtk Herpes Simplex Virus Thymidine Kinase
  • constructs containing the HSVtk promoter in place of the SV40 promoter were prepared by replacing the SV40 promoter in the respective parent plasmid with the HSVtk promoter from pRL-TK as described for pGL3/HSVtk.
  • the first variant of the luciferase reporter construct carried a strong promoter, in this specific example the SV40 promoter.
  • the second variant of the luciferase reporter construct carried a basal promoter, in this specific example the HSVtk promoter.
  • ARE androgen response element
  • both SV40 and HSVtk promoters were coupled to four different AREs, C3 , DR-1 (IX and 2X) and PB-ARE.
  • the C3 enhancer is a strong androgen dependent regulatory element with a crossover activity with Glucocorticoid Receptor (GR) . Both DR-1 and PB-ARE are considered to be specific androgen response elements.
  • a transient transactivation experiment was performed in which CMVrAR was cotransfected with the aforementioned enhancer/promoter/reporter construct (10:1 receptor to enhancer/promoter/reporter) in C2C12 cells using LipofectAMINE PlusTM reagent (GibcoBRL) according to the manufacturer's instructions was used to compare the activities of the enhancer/promoter/reporter constructs. Specifically, 10,000 cells/well were plated in growth media (Dulbecco's modified Eagle Medium (DMEM) high glucose supplemented with 10% FBS, IX sodium pyruvate and 0.5X antibiotic-antimycotic (all from GibcoBRL) ) . The next day, the media was removed and replaced with optiMEM media (Gibco BRL) . The transfection mixture was prepared so that

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des lignées cellulaires musculaires stables comprenant un récepteur androgène, et des méthodes d'utilisation de ces cellules dans des dosages de transactivation fonctionnelle permettant d'évaluer l'efficacité de composés comme modulateurs de récepteurs androgènes dans un échantillon de contrôle musculaire.
EP01944616A 2000-06-28 2001-06-20 Lignees cellulaires et dosages a base de cellules permettant d'identifier des modulateurs de recepteurs d'androgenes Withdrawn EP1297108A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21439200P 2000-06-28 2000-06-28
US214392P 2000-06-28
PCT/US2001/019609 WO2002000716A2 (fr) 2000-06-28 2001-06-20 Lignees cellulaires et dosages a base de cellules permettant d'identifier des modulateurs de recepteurs d'androgenes

Publications (1)

Publication Number Publication Date
EP1297108A2 true EP1297108A2 (fr) 2003-04-02

Family

ID=26680504

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01944616A Withdrawn EP1297108A2 (fr) 2000-06-28 2001-06-20 Lignees cellulaires et dosages a base de cellules permettant d'identifier des modulateurs de recepteurs d'androgenes

Country Status (6)

Country Link
EP (1) EP1297108A2 (fr)
JP (1) JP2004517606A (fr)
AU (1) AU2001267008A1 (fr)
CA (1) CA2413596A1 (fr)
MX (1) MXPA02012573A (fr)
WO (1) WO2002000716A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8821301A (en) 2000-06-28 2002-01-08 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification, design and use
EP1359160A1 (fr) * 2002-02-28 2003-11-05 Pfizer Products Inc. Myoblastes squelettiques, qui surexpriment un récepteur androgène
MXPA05000647A (es) * 2002-07-17 2005-03-31 Squibb Bristol Myers Co Mamiferos no humanos transgenicos que expresan un acido nucleico reportero bajo regulacion de los elementos de respuesta de androgenos.
US8623909B2 (en) * 2008-05-09 2014-01-07 Aska Pharmaceutical Co., Ltd. Prophylactic/therapeutic agents for lifestyle-related diseases
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
CN105758916B (zh) * 2016-03-16 2018-04-13 济南大学 一种基于电化学发光激发的溴氰菊酯光电化学传感器的制备方法及应用
CN115181748A (zh) * 2022-08-08 2022-10-14 湖州师范学院 一种雄性激素的生物学检测方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US6492137B1 (en) * 1989-11-16 2002-12-10 The Salk Institute For Biological Studies Response element compositions and assays employing same
EP0832269A1 (fr) * 1995-06-07 1998-04-01 Baylor College Of Medicine Transporteurs d'acide nucleique servant a introduire des acides nucleiques dans une cellule
JP2002512368A (ja) * 1998-04-23 2002-04-23 カロ バイオ ユー エス エイ，インコーポレイテッド 受容体の生物活性を調節するための化合物の能力を予測する方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0200716A2 *

Also Published As

Publication number Publication date
AU2001267008A1 (en) 2002-01-08
JP2004517606A (ja) 2004-06-17
MXPA02012573A (es) 2003-05-14
CA2413596A1 (fr) 2002-01-03
WO2002000716A3 (fr) 2002-06-13
WO2002000716A2 (fr) 2002-01-03

Similar Documents

Publication Publication Date Title
Bliziotes et al. Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake
van Driel et al. Evidence that both 1α, 25‐dihydroxyvitamin D3 and 24‐hydroxylated D3 enhance human osteoblast differentiation and mineralization
Scott et al. Molecular cloning of the bovine prolactin receptor and distribution of prolactin and growth hormone receptor transcripts in fetal and utero-placental tissues
Cheung-Flynn et al. Physiological role for the cochaperone FKBP52 in androgen receptor signaling
Kang et al. cAMP-regulated guanine nucleotide exchange factor II (Epac2) mediates Ca2+-induced Ca2+ release in INS-1 pancreatic β-cells
Myers et al. Nuclear trafficking of FGFR1: a role for the transmembrane domain
Wang et al. Epigenetic status determines germ cell meiotic commitment in embryonic and postnatal mammalian gonads
KR20020073141A (ko) 인히빈 수용체로서의 베타글리칸 및 이의 용도
EP1297108A2 (fr) Lignees cellulaires et dosages a base de cellules permettant d'identifier des modulateurs de recepteurs d'androgenes
US20020058290A1 (en) Cell lines and cell-based assays for identification of androgen receptor modulators
Nakagawa et al. Progesterone receptor antagonists with a 3-phenylquinazoline-2, 4-dione/2-phenylisoquinoline-1, 3-dione skeleton
Busby et al. Discovery of inverse agonists for the liver receptor homologue-1 (LRH1; NR5A2)
Pellegrino et al. WNT4 signaling in female gonadal development
Gessi et al. Glucocorticoids' pharmacology: past, present and future
Rudnik et al. Loss of ERE binding activity by estrogen receptor‐α alters basal and estrogen‐stimulated bone‐related gene expression by osteoblastic cells
Kakar et al. Geldanamycin, an inhibitor of Hsp90, blocks cytoplasmic retention of progesterone receptors and glucocorticoid receptors via their respective ligand binding domains
Chaudhary et al. Role of the transcriptional coactivator CBP/p300 in linking basic helix-loop-helix and CREB responses for follicle-stimulating hormone-mediated activation of the transferrin promoter in Sertoli cells
CA2522718A1 (fr) Nouveau procede de modulation de l'activite liee a l'os
KR20030021172A (ko) 스테로이드 수용체의 유전자자극 활성으로부터비유전자자극성을 분리하기 위한 방법
Misund et al. Inducible cAMP early repressor splice variants ICER I and IIγ both repress transcription of c‐fos and chromogranin A
US20100285032A1 (en) Estrogen receptor-related receptor gamma (err gamma) in bone and cartilage formation and methods and compositions relating to same
WO2010141430A2 (fr) Récepteur transmembranaire cloné de composés de vitamine d 24-hydroxylés et leurs utilisations
Shima Effects of androgen on α-and β-adrenergic receptors in membranes from the rat seminal vesicle
US20050244859A1 (en) Cell based assay
Narayana Role of Epigenetic Modifications and Dexras1 in glucocorticoid regulation of growth hormone expression

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021209

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20030620